CROSSJECT (FRA:74C) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


FRA:74C CROSSJECT FRA:74C
42 GF Score
Price €1.76
GF Value €1.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CROSSJECT Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

CROSSJECT's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:74C vs ISRG, BDX, MDLN: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Instruments & Supplies subindustry, CROSSJECT's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CROSSJECT Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CROSSJECT's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where CROSSJECT's Margin of Safety % (DCF FCF Based) falls into.


FRA:74C
42GF Score
CROSSJECT FRA:74C
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CROSSJECT (FRA:74C) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.76 is trading 57.3% above its estimated GF Value™ of €1.12. GuruFocus considers CROSSJECT to be Significantly Overvalued.

Key valuation signals for FRA:74C:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €1.12 vs. price of €1.76 (57.3% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:74C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CROSSJECT Business Description

Other Exchanges ALCJ:France74C:Germany
Address 60L avenue du 14 Juillet, Chenôve, FRA, 21300
CROSSJECT manufactures and markets needle-free drug self-injection system.
42GF Score

Get the complete analysis for FRA:74C

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.76
Price
€1.12
GF Value